Last reviewed · How we verify
Mirabegron tablet
Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.
Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.
At a glance
| Generic name | Mirabegron tablet |
|---|---|
| Also known as | YM178 |
| Sponsor | Astellas Pharma Inc |
| Drug class | Beta-3 adrenergic receptor agonist |
| Target | Beta-3 adrenergic receptor (ADRB3) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Mirabegron activates beta-3 adrenergic receptors on the smooth muscle of the bladder detrusor, causing relaxation and increased bladder capacity during the storage phase of the micturition cycle. Unlike anticholinergic agents, it does not block muscarinic receptors, providing an alternative mechanism for treating overactive bladder symptoms. This sympathomimetic approach allows increased urine storage without the anticholinergic side effects associated with traditional overactive bladder medications.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency
Common side effects
- Hypertension
- Headache
- Nasopharyngitis
- Dizziness
- Tachycardia
- Urinary tract infection
Key clinical trials
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion (PHASE4)
- Activation of Brown Adipose Tissue Metabolism Using Mirabegron (NA)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (PHASE3)
- A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirabegron tablet CI brief — competitive landscape report
- Mirabegron tablet updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI